Cardiovascular outcomes in diabetic kidney disease: insights from recent clinical trials

Area of Science:

• Endocrinology
• Cardiology
• Nephrology

Background:

• Type 2 diabetes (T2DM) is a major driver of global kidney disease and cardiovascular complications.
• Existing treatments primarily focus on glycemic control, necessitating novel approaches for broader patient benefits.
• Diabetic kidney disease (DKD) significantly increases cardiovascular risk in T2DM patients.

Purpose of the Study:

• To review the cardiovascular benefits of novel antidiabetic agents beyond glucose lowering.
• To compare the distinct cardiovascular outcome profiles of SGLT2 inhibitors and GLP-1 receptor agonists.
• To explore ongoing research into the mechanisms and optimal use of these drug classes.

Main Methods:

• Review of recent cardiovascular outcome trials (CVOTs) involving T2DM patients.
• Analysis of data on SGLT2 inhibitors and GLP-1 receptor agonists.
• Discussion of current understanding of mechanistic pathways and future research directions.

Main Results:

• Sodium-glucose cotransporter 2 inhibitors (SGLT2is) demonstrated a reduction in heart failure risk and cardiovascular death.
• Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were associated with decreased risk of myocardial infarction and cardiovascular death.
• Both drug classes offer benefits independent of their glucose-lowering effects in patients with T2DM, including those with DKD.

Conclusions:

• SGLT2is and GLP-1 RAs represent significant advancements in managing T2DM, offering substantial cardiovascular protection.
• These agents provide distinct cardiovascular benefits, suggesting tailored therapeutic strategies may be beneficial.
• Further research is crucial to confirm class effects, elucidate mechanisms, and define optimal treatment timing and patient populations for these novel antidiabetic therapies.